FIELD: medical biotechnology.
SUBSTANCE: present invention relates to medical biotechnology, namely to a method for inhibition of proliferation of cancer stem cell (hereinafter – CSC). The method includes bringing CSC into a contact with antibody to lectin-like receptor 1 of oxidized LDL (LOX1) containing a set of complementarity determining regions (hereinafter – CDR): variable region of the heavy chain (VH)-CDR1, VH-CDR2, VH-CDR3, and variable region of the light chain (VL)-CDR1, VL-CDR2 and VL-CDR3 with SEQ ID NO: 1-3; SEQ ID NO:30-32 in an amount effective for inhibiting proliferation and/or weakening CSC survival.
EFFECT: method provides for better clinical results, such as remission of the disease and/or improvement of the patient’s life quality.
13 cl, 26 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LOX1-SPECIFIC BINDING PROTEINS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764993C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| ANTI-TUMOUR ANTIGEN ANTIBODY AND METHODS OF APPLICATION | 2011 |
|
RU2598711C2 |
| ANTIBODIES TO INTERLEUKIN-6 AND USES THEREOF | 2013 |
|
RU2656162C2 |
| NECTIN-4 BINDING PROTEINS AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2805252C2 |
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER | 2008 |
|
RU2682285C2 |
| ANTI-KIT ANTIBODIES AND USES THEREOF | 2013 |
|
RU2681730C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| ANTIBODIES TO MST1R AND THEIR APPLICATION | 2010 |
|
RU2534890C2 |
